Creative Biolabs Launched Comprehensive ADC in vitro Analysis Service

SHIRLEY, NY, UNITED STATES - Nov 30, 2017 - Recently, Creative Biolabs, a professional antibody company with years of experience, has launched a brand new ADC in vitro analysis service, aiming to provide a guideline for ADC optimization and the downstream in vivo ADC assessment and a high-quality one-stop service for their clients around the world. 

Three major components define an ADC-the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. The ultimate goal for an ADC development project is to deploy the resulted ADC into in vivo systems, both in model animals and eventually human patients, to cure cancer and other diseases utilizing its payload efficacy. 

“However, prior to in vivo deployment, information regarding basic biochemical characteristics and in vitro efficacy must be acquired for a proper evaluation of the ADC to determine the proceedings and directions of the project. And that’s how we work. ” said Dr. Monika Müller, Scientific Officer of Creative Biolabs.

“Our team offers a comprehensive portfolio of ADC in vitro analysis services to help our clients determine the in vitro efficacy of an ADC product. Meanwhile, we also provide a guideline for project progression. Our ADC analysis services are divided into three parts as follows, biochemical analysis, in vitro efficacy evaluation and 3D vitro. ”

Compared to traditional therapeutic methods, monoclonal antibody-based immunotherapies against cancer and other infectious diseases are more effective due to their high affinity and specificity towards well-defined targets. Based on our advanced high-resolution analytical platforms and experienced technical staff, the analytical division at Creative Biolabs is fully competent and dedicated to serving as your one-stop-shop for ADC in vitro analysis and characterizations.

About Creative Biolabs

Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, preclinical evaluations, cGMP manufacturing, to clinical trails. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world.